# A Study of HNC664 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics

> **NCT04504448** · PHASE1 · COMPLETED · sponsor: **Guangzhou Henovcom Bioscience Co. Ltd.** · enrollment: 45 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** HNC664 capsules Single dose
- **DRUG:** HNC664 placebos Single dose
- **DRUG:** HNC664 capsules FED

## Key facts

- **NCT ID:** NCT04504448
- **Lead sponsor:** Guangzhou Henovcom Bioscience Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-11
- **Primary completion:** 2021-07-13
- **Final completion:** 2021-07-13
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2022-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04504448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04504448, "A Study of HNC664 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04504448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*